Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
22.60
+0.20 (0.89%)
Jun 6, 2025, 5:39 PM CET
7.11%
Market Cap 903.44M
Revenue (ttm) 77.65M
Net Income (ttm) 45.29M
Shares Out 40.33M
EPS (ttm) 1.12
PE Ratio 20.00
Forward PE 10.28
Dividend n/a
Ex-Dividend Date n/a
Volume 24,642
Average Volume 10,026
Open 22.50
Previous Close 22.40
Day's Range 22.40 - 23.10
52-Week Range 16.50 - 23.00
Beta 0.15
RSI 63.09
Earnings Date Sep 23, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. The company is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine inter... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 165
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.